Jane Street Group, LLC Tricida, Inc. Transaction History

Jane Street Group, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 16, 2022	SELL	$7.31 - $11.85 $803,668 - $1.3 Million	-109,941 Closed	0 $0
Q1 2022 May 17, 2022	BUY	$7.35 - $10.63 $630,600 - $912,011	85,796 Added 355.34%	109,941 $904,000
Q4 2021 Feb 15, 2022	BUY	$4.19 - $9.56 $101,167 - $230,826	24,145 New	24,145 $231,000
Q2 2021 Aug 16, 2021	SELL	$3.95 - $5.41 $67,584 - $92,565	-17,110 Closed	0 $0
Q1 2021 May 18, 2021	SELL	$4.52 - $7.8 $1,148 - $1,981	-254 Reduced 1.46%	17,110 $91,000
Q4 2020 Feb 17, 2021	BUY	$4.37 - $9.46 $75,880 - $164,263	17,364 New	17,364 $122,000

30K

124K

46.5K

Ticker TCDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,668,900
Market Cap $557K
Description
Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company ...

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

Stay updated on Jane Street Group, LLC with notifications on news.